Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 10 Other solid neoplasm 8 Gynecologic 7 Other hematologic neoplasm 5 Tumor-Agnostic 4 Thoracic 4 Genitourinary 4 Gastrointestinal 4 Myeloid 2 Sarcoma 1 NET 1 Lymphoid 1 Head & Neck 1 Endocrine 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 15 Magnetic Resonance Spectroscopy 8 lutetium Lu 177 dotatate 7 pasireotide 5 gallium Ga 68 dotatate 5 Cisplatin 5 Specimen Handling 4 Positron Emission Tomography Computed Tomography 4 Nivolumab 4 Fluorodeoxyglucose F18 4 Carboplatin 4 Temozolomide 3 Paclitaxel 3 Octreotide 3 Lutetium-177 3 Ga(III)-DOTATOC 3 Etoposide 3 (177)Lu-DOTA-EB-TATE 3 vandetanib 2 pembrolizumab 2 olaparib 2 fluorodopa F 18 2 dabrafenib 2 copper dotatate CU-64 2 cemiplimab 2 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Trastuzumab 2 Radiotherapy 2 Radiosurgery 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × talazoparib × Endocrine × Clear all

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡